Drug intelligence / Profile preview

YR-201

Development stage: Preclinical
Lead developer: Hangzhou Yirui Pharmaceutical Technology
Modality: Small Molecules
Administration: Inhalation, Ophthalmic

Overview

YR-201 is a small molecule drug under development as a modulator of G-protein coupled receptors (GPCRs). It was initially developed by Hangzhou Yirui Pharmaceutical Technology. The drug is in preclinical stages and is being investigated for the treatment of eye diseases (including retinal diseases and ocular inflammation) and respiratory diseases (notably chronic obstructive pulmonary disease). Its mechanism of action involves modulation of GPCR signaling pathways[1].

Beyond the preview

Go deeper on YR-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YR-201.

Explore the full profile